Skip to content

MeiraGTx Holdings plc MGTX Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

PVL
Palvella TherapeuticsPVLA
$38.5K
Nektar Therapeutics logo
Nektar TherapeuticsNKTR

Other financials

Income statement

See full
Revenue$293.0K-84.8%
Operating income-$40.8M+1.9%
Net income-$46.3M-15.8%
EPS (diluted)-$0.57-11.8%

Balance sheet

See full
Cash & equivalents$71.5M+7.5%
Total debt$62.7M-22.5%
Total equity-$58.1M-276%
Total assets$244.7M+9.2%

Cash flow

See full
Operating cash flow$17.8M+148%
CapEx$2.0M+17.4%
Free cash flow$15.8M+141%

Valuation

See full
Market cap$1.07B+31.9%
Enterprise value$1.07B+26.9%
P/S13.5×-10.1×

Profitability

See full
Operating margin-597.9%-207pp
Net margin-615.3%
FCF margin-441.5%-126pp

Returns & leverage

See full
Return on equity-379.5%
Debt / equity27.2×+26.1×
Current ratio0.5×-1.0×

Where this comes from

Reported directly by MeiraGTx Holdings plc in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: MeiraGTx Holdings plc’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MeiraGTx Holdings plc's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MeiraGTx Holdings plc's payments of stock issuance costs?
MeiraGTx Holdings plc (MGTX) reported payments of stock issuance costs of $35K in Q1 2026.
How has MeiraGTx Holdings plc's payments of stock issuance costs changed year-over-year?
MeiraGTx Holdings plc's payments of stock issuance costs increased by 191.7% year-over-year, from $12K to $35K.
What does payments of stock issuance costs mean?
Represents the direct costs incurred, such as legal, accounting, and underwriting fees, associated with raising capital through the issuance of equity. Tracking these costs is essential for evaluating the efficiency of the company's financing activities. High issuance costs relative to proceeds can indicate less favorable market access or complex capital raising processes.